Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 2 , Pages 80-88 , March 2008

Partnership between academia and industry for drug discovery in Alzheimer’s disease

  • Adrian J. Ivinson

      Affiliations

    • Harvard NeuroDiscovery Center, Harvard Medical School, Boston, MA, USA
    • ,
  • Roger Lane

      Affiliations

    • Novartis, East Hanover, NJ, USA
    • ,
  • Patrick C. May

      Affiliations

    • Eli Lilly & Co, Indianapolis, IN, USA
    • ,
  • David A. Hosford

      Affiliations

    • Targacept, Inc, Winston-Salem, NC, USA
    • ,
  • Maria C. Carrillo

      Affiliations

    • Alzheimer’s Association, Chicago, IL, USA
    • Corresponding Author InformationCorresponding author: Tel.: 312-335-5722; Fax: 866-741-3716.
    • ,
  • Eric R. Siemers

      Affiliations

    • Eli Lilly & Co, Indianapolis, IN, USA

References 

  1. Alzheimer’s Disease Facts and Figures, 2007. http://www.alz.org/alzheimers_disease_facts_figures.asp
  2. Drews J. Drug discovery: a historical perspective. Science. 2000;287:1960–1964
  3. Hopkins AL, Groom CR. Perspectives: the druggable genome. Nat Rev. 2002;1:727–730
  4. Austin CP, Brady LS, Insel TR, Collins FS. NIH Molecular Libraries Initiative. Science. 2004;306:1138–1139
  5. Drews J. Strategic trends in the drug industry. Drug Discov Today. 2003;8:411–420
  6. Atterwill CK, Wing MG. Lead optimization in pharmaceutical development: molecular and cellular approaches. In:  Swarbrick J editors. Encyclopedia of pharmaceutical technology. 3rd ed.. New York: Informa Healthcare, USA, Inc; 2006;
  7. Strnadova C. Assessment of QT/QTc interval prolongation in clinical trials: a regulatory perspective. The Drug Information Journal. 2005;Available at: http://www.encyclopedia.com/doc/1P3-930868551.html
  8. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774–1782
  9. Elkins S, Nikolsky Y, Nikolskaya T. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci. 2005;26:202–209
  10. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev. 2004;3:226–236
  11. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69:297–307
  12. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm. 2002;109:1053–1065
  13. Shaw LM, Korecka M, Clark CM, Lee VM-Y, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev. 2007;6:295–303
  14. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, et al. Alzheimer Dis Assoc Disord. 2006;20:6–15
  15. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Assi M, et al. Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28:537–547
  16. Aisen PS, Saumier D, Briand R, Laurin F, Gervais F. A Phase II study targeting amyloid-B with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67:1757–1763
  17. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, et al. Alzhemed: a potential treatment for Alzheimer’s disease. Current Alzheimer’s Research. 2007;4:473–478
  18. Zavitz KH, Hendrix S, Laughlin M, Swabb E. A responder analysis of MPC-7869 (Tarenflubil), a selective AB42-lowering agent, in mild Alzheimer’s disease (AD): analysis from a Phase 2 study of up to 24 months of treatment. Alzheimer’s & Dementia. 2007;3:S99–S100
  19. Mohs RC, Kawas C, Carrillo MC. Optimal design of clinical trials for drugs designed to slot the course of Alzheimer’s disease. Alzheimer’s & Dementia. 2006;2:131–139
  20. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med. 1992;327:1253–1259
  21. Thal LJ. The Alzheimer’s Disease Cooperative Study in 2004. Alzheimer Dis Assoc Disord. 2004;18:183–185
  22. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, et al. Mild cognitive impairment can be distinguished from Alzheimer’s disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66
  23. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA. 2000;283:1007–1015
  24. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. JAMA. 2003;289:2819–2826
  25. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris SH, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  26. Steinberg D. An interpretive history of the history of cholesterol controversy: part1. J Lipid Res. 2004;45:1583–1593
  27. Ivinson AJ. University investment in drug discovery. (letter) Science. 2005;310:777

PII: S1552-5260(08)00029-0

doi: 10.1016/j.jalz.2008.02.004

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 2 , Pages 80-88 , March 2008

Article Tools

* Image Usage & Resolution